| 纯度 | >90%SDS-PAGE. |
| 种属 | E. coli |
| 靶点 | AGMAT |
| Uniprot No | B7LFJ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-306aa |
| 氨基酸序列 | MSTLGHQYDNSLVSNAFGFLRLPMNFQPYDSDADWVITGVPFDMATSGRA GGRHGPAAIRQVSTNLAWEHNRFPWNFDMRERLNVVDCGDLVYAFGDARE MSEKLQAHAEKLLAAGKRMLSFGGDHFVTLPLLRAHAKHFGKMALVHFDA HTDTYANGCEFDHGTMFYTAPKEGLIDPNHSVQIGIRTEFDIDNGFTVLD ACQVNDRSVDDVIAQVKQIVGDMPVYLTFDIDCLDPAFAPGTGTPVIGGL TSDRAIKLVRGLKDLNIVGMDVVEVAPAYDQSEITALAAATLALEMLYIQ AAKKGE |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AGMAT重组蛋白的模拟参考文献示例(信息为学术示例，非真实文献)：
1. **文献名称**：*Expression and Purification of Recombinant AGMAT Protein in E. coli*
**作者**：Smith J, et al.
**摘要**：本研究报道了通过大肠杆菌表达系统高效生产AGMAT重组蛋白的优化方法，利用His标签纯化技术获得高纯度蛋白，并验证其催化精氨酸脱羧生成胍基丁胺的酶活性。
2. **文献名称**：*AGMAT Recombinant Protein Alleviates Neuropathic Pain in Rodent Models*
**作者**：Chen L, et al.
**摘要**：通过体外表达AGMAT重组蛋白并注射至神经损伤模型大鼠，发现其显著抑制脊髓胶质细胞活化，降低炎症因子释放，为AGMAT的镇痛机制提供了实验依据。
3. **文献名称**：*Structural Characterization of Human AGMAT by X-ray Crystallography*
**作者**：Wang Y, et al.
**摘要**：首次解析了人源AGMAT重组蛋白的晶体结构，揭示其活性中心关键氨基酸残基，为开发靶向AGMAT的小分子药物奠定结构基础。
4. **文献名称**：*AGMAT Recombinant Protein Enhances Cellular Stress Resistance*
**作者**：Kim S, et al.
**摘要**：在细胞模型中证实外源性AGMAT重组蛋白通过激活AMPK/mTOR通路提高氧化应激耐受性，提示其在代谢性疾病治疗中的潜在应用价值。
---
注：以上内容为模拟示例，实际文献需通过学术数据库检索确认。
Agmatine (AGMAT) recombinant protein is a biologically engineered molecule derived from the agmatinase enzyme, which plays a critical role in regulating agmatine metabolism. Agmatine, a biogenic amine synthesized from L-arginine via arginine decarboxylase, acts as a neurotransmitter, neuromodulator, and cytoprotective agent in mammals. It interacts with multiple receptors, including α2-adrenergic receptors, imidazoline receptors, and NMDA receptors, influencing processes like pain modulation, neuroprotection, and cellular stress responses. The enzyme AGMAT catalyzes the hydrolysis of agmatine to putrescine and urea, thereby regulating polyamine biosynthesis and nitric oxide synthase activity.
Recombinant AGMAT protein is produced using expression systems such as Escherichia coli or mammalian cell cultures, enabling large-scale production for research and therapeutic applications. Its recombinant form retains enzymatic activity and structural stability, allowing scientists to study its biochemical properties, substrate specificity, and regulatory mechanisms in vitro. This protein is particularly valuable in investigating conditions linked to agmatine dysregulation, such as neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), chronic pain syndromes, and metabolic disorders.
Recent studies highlight AGMAT's potential therapeutic roles. For instance, modulating agmatine levels via recombinant AGMAT could offer strategies to mitigate neuroinflammation, enhance cognitive function, or manage opioid tolerance. Additionally, its involvement in polyamine metabolism links it to cancer research, where altered polyamine levels are common in tumorigenesis. The development of AGMAT recombinant protein also supports drug discovery, enabling high-throughput screening for inhibitors or activators to fine-tune agmatine-related pathways. Overall, AGMAT recombinant protein serves as a vital tool in bridging molecular biology with translational medicine, offering insights into both fundamental biochemistry and clinical interventions.
×
